Gene · 28695
TRAJ60: T cell receptor alpha joining 60 (pseudogene)
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. TRAJ60: T cell receptor alpha joining 60 (pseudogene). Genes, record 28695. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/28695
On this page
Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,845
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TRAJ60 papers | Newest fiscal year |
|---|---|---|---|
| U19AI057229 | Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | 22 | 2025 |
| R01AI049313 | T cell responses to CD1-restricted lipids in tuberculosis | 20 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 18 | 2025 |
| R01AI045889 | Precision Targeting of CD1-Restricted iNKT Cells for Cancer Immunotherapy | 16 | 2025 |
| ZIABC010984 | Adoptive Cell Transfer Immunotherapy of Cancer | 16 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| R01AI136514 | DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC | 15 | 2025 |
| ZICBC010948 | DNA Sequencing and FACS Core Facilities | 14 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 12 | 2025 |
| ZIABC010985 | Gene therapy of cancer | 12 | 2025 |
1 to 10 of 2,845Source NIH's project files
See all 2,845 nih grantsPapers3,708
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Systematic analysis of CDR contacts and pairing constraints between T cell receptor αβ chains. | Bioinformatics | 2026 | 42485223 | PubTator, text mining | PubMed |
| T-cell receptor alpha to beta chains binding prediction. | Brief Bioinform | 2026 | 42418829 | PubTator, text mining | PubMed |
| Human neonatal MR1T cells have more diverse TCR repertoires but reduced bacterial recognition than adult MR1T cells. | Nat Commun | 2026 | 42373629 | PubTator, text mining | PubMed |
| Preselection CD4+CD8+ thymocytes modulate TCR responsiveness following TCRβ selection. | J Immunol | 2026 | 42285890 | PubTator, text mining | PubMed |
| Clonal overlap and convergent clustering of T cell receptor signatures in Crohn's disease in monozygotic twins. | Inflamm Bowel Dis | 2026 | 42243622 | PubTator, text mining | PubMed |
| Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. | ACS Nano | 2026 | 41990155 | PubTator, text mining | PubMed |
Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs. | Clin Pract | 2026 | 41892490 | PubTator, text mining | PubMed |
| γδ T cells at the interface of innate and adaptive immunity in cancer. | J Immunother Cancer | 2026 | 41871873 | PubTator, text mining | PubMed |
| Dengue infection elicits skin tissue-resident and circulating CD8+ T cells associated with protection from hospitalization. | Sci Adv | 2026 | 41861003 | PubTator, text mining | PubMed |
| Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. | Science | 2026 | 41855322 | PubTator, text mining | PubMed |
1 to 10 of 3,708
See all 3,708 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/28695
GET https://conductscience.org/api/genes/v1/28695/grants?page=2